Physician profile
Supen Patel
NPI 1114969359
$148,532.84
in general payments reported to CMS, 2019-2025
23 companies · $25K in 2025
The $25K reported for 2025 was more than what 93% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67K · 2020: $9,333 · 2021: $6,869 · 2022: $17K · 2023: $16K · 2024: $7,404 · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Food and Beverage: $4,672 · Travel and Lodging: $2,788 · Consulting Fee: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,125.00 |
| Food and Beverage | $4,672.10 |
| Travel and Lodging | $2,788.03 |
| Consulting Fee | $375.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $120,708.29 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $13,065.08 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $5,694.08 | 2019 | |
| Horizon Therapeutics Plc | $1,582.80 | 2019-2023 | Krystexxa |
| Amgen INC. | $1,527.39 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Genzyme Corporation | $1,413.84 | 2020-2021 | |
| Pfizer INC. | $837.78 | 2019-2025 | |
| Glaxosmithkline, LLC. | $690.93 | 2019-2023 | Benlysta |
| Celgene Corporation | $652.05 | 2019 | |
| Janssen Biotech, INC. | $619.12 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $404.06 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $392.27 | 2019-2024 | Orencia |
| Forte Bio-Pharma LLC | $346.08 | 2020-2025 | Prolate, Nalocet, Tanlor |
| Ucb, INC. | $290.10 | 2019-2024 | Cimzia |
| Janssen Pharmaceuticals, INC | $105.35 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $64.65 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $35.20 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.77 | 2019-2025 | Ofev |
| Radius Health, INC. | $17.31 | 2019 | |
| Sandoz INC. | $16.44 | 2023 | |
| Lilly USA, LLC | $15.92 | 2019 | |
| Alexion Pharmaceuticals, INC. | $14.35 | 2019 | |
| Hikma Pharmaceuticals USA | $12.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Supen Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.